Oxford-based start-up Caristo Diagnostics has secured $16.3 million in Series A funding from a group of investors including Oxford Science Enterprises, BGF, Oxford Investment Consultants, University of Oxford, and Longwall Venture Partners LLP. Caristo Diagnostics is focused on bringing revolutionary cardiovascular diagnostic tools to patients worldwide, leveraging proprietary technology to transform the accuracy of routine cardiac CT scans.

Caristo Diagnostics' innovative technology extracts new information from cardiac CT scans that is otherwise invisible, providing enhanced capabilities to predict cardiovascular risk and refine treatment decisions. By leveraging advanced imaging techniques, Caristo Diagnostics aims to improve the accuracy and effectiveness of cardiovascular disease diagnosis and management, ultimately leading to better patient outcomes.

The funding raised in this Series A round will be used to further develop and commercialize Caristo Diagnostics' diagnostic tools, expand its team, and advance its clinical studies.

Caristo Diagnostics envisions a future where its technology is widely adopted in clinical practice, helping to identify and manage the cardiovascular disease more accurately and efficiently.

For more information on Caristo Diagnostics and its mission to revolutionize cardiovascular diagnostics, visit their latest funding round at https://founderlodge.com/round/Caristo-Diagnostics-raises-16300000-Series-A-2023-04-18-Frank-Cheng-MTIyNjI